Media Contact: Lissa Pavluk media@apellis.com (617) 977-6764
- January 2, 2024 Apellis Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- December 28, 2023 Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs Healthcare C-Suite Unscripted Conference
- December 14, 2023 Apellis Provides Update on Ongoing Regulatory Review of Pegcetacoplan for GA in the European Union
- December 11, 2023 EMPAVELI® (pegcetacoplan) Provided Long-Term Control of PNH in New Data Presented at ASH Annual Meeting
- December 6, 2023 Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- November 21, 2023 Apellis Pharmaceuticals to Host a Fireside Chat at the 6th Annual Evercore ISI HealthCONx Conference
- November 6, 2023 Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- November 4, 2023 SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 3 Years in Patients with Geographic Atrophy (GA)
- November 1, 2023 Apellis Pharmaceuticals Reports Third Quarter 2023 Financial Results
- October 25, 2023 Apellis Pharmaceuticals to Host Conference Call on November 1, 2023, to Discuss Third Quarter 2023 Financial Results
Displaying 41 - 50 of 305